Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDEXX LaboratoriesLTS:0J8P +3.00%95 Cyclically Adjusted PS Ratio is 14.54 as of Aug. 04, 2026, which is 2% below its 10-year median of 14.78. GuruFocus rates LTS:0J8P with a GF Score™ of 95/100 and a GF Value™ of $642.11 (Modestly Undervalued). Among 135 Medical Diagnostics & Research companies, IDEXX Laboratories ranks worse than 89.63% on this metric.
The historical rank and industry rank for IDEXX Laboratories's Cyclically Adjusted PS Ratio or its related term are showing as below:
LTS:0J8P'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 8.56 Med: 14.78 Max: 30.79
Current: 13.76
During the past years, IDEXX Laboratories's highest Cyclically Adjusted PS Ratio was 30.79. The lowest was 8.56. And the median was 14.78.
LTS:0J8P's Cyclically Adjusted PS Ratio is ranked worse than 89.63% of 135
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.88
vs LTS:0J8P: 13.76
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
IDEXX Laboratories's adjusted revenue per share data for the three months ended in Mar. 2026 was $14.231. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $40.97 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
IDEXX Laboratories (LTS:0J8P) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
IDEXX Laboratories Cyclically Adjusted PS Ratio Related Terms
IDEXX Laboratories Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories Cyclically Adjusted PS Ratio Chart
LTS:0J8P vs A, NTRA, WAT: Cyclically Adjusted PS Ratio Comparison
For the Diagnostics & Research subindustry, IDEXX Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's Cyclically Adjusted PS Ratio falls into.
IDEXX Laboratories Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
IDEXX Laboratories's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 14.54 mean?
IDEXX Laboratories (LTS:0J8P) has a Cyclically Adjusted PS Ratio of 14.54 as of Aug. 04, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on IDEXX Laboratories and its competitors. This is near median its historical median of 14.78. Over the past decade, IDEXX Laboratories' Cyclically Adjusted PS Ratio has ranged from 8.56 to 30.79. According to the industry distribution chart, IDEXX Laboratories ranks #121 out of 135 companies in the Medical Diagnostics & Research industry, placing it in the top 89.6%.
Is IDEXX Laboratories' Cyclically Adjusted PS Ratio too high?
IDEXX Laboratories' current Cyclically Adjusted PS Ratio of 14.54 is near median its 10-year median of 14.78. Over the past 10 years, this metric has ranged from a low of 8.56 to a high of 30.79. The Medical Diagnostics & Research industry median Cyclically Adjusted PS Ratio is 1.88. IDEXX Laboratories' value of 14.54 is 673.4% above this industry median. Based on the distribution chart, IDEXX Laboratories ranks #121 out of 135 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Cyclically Adjusted PS Ratio compare to A and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #121 out of 135 companies for Cyclically Adjusted PS Ratio. This places IDEXX Laboratories in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 1.88. IDEXX Laboratories' value of 14.54 is 673.4% above this benchmark. Historically, IDEXX Laboratories' own Cyclically Adjusted PS Ratio has ranged from 8.56 to 30.79 over the past decade. While the company's 10-year median is 14.78 vs. the industry median of 1.88, IDEXX Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Diagnostics & Research company?
The median Cyclically Adjusted PS Ratio among Medical Diagnostics & Research companies is 1.88, based on 135 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current Cyclically Adjusted PS Ratio of 14.54 is 673.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted PS Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current Cyclically Adjusted PS Ratio is 14.54, which is near median its own 10-year median of 14.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (LTS:0J8P) is currently considered Modestly Undervalued. The stock's GF Value™ is $642.11, compared to a current price of $595.66 — trading 7.2% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 14.54, which is near median its 10-year median of 14.78 and 673.4% above the Medical Diagnostics & Research industry median of 1.88. IDEXX Laboratories' overall GF Score™ is 95/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For IDEXX Laboratories (LTS:0J8P), the current Cyclically Adjusted PS Ratio is 14.54 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (LTS:0J8P) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of $595.66 is trading 7.2% below its estimated GF Value™ of $642.11.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for LTS:0J8P:
Cyclically Adjusted PS Ratio: 14.54 (near median its 10-year median of 14.78)
GF Value™: $642.11 vs. price of $595.66 (7.2% below fair value)
Industry Position: 673.4% above the Medical Diagnostics & Research median (#121 of 135)
No single metric tells the full story. See the LTS:0J8P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
95GF Score
Get the complete analysis for LTS:0J8P
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0J8P has been successfully added to your 
